SCHEMBL2470833

SCHEMBL2470833

CCOC(=O)c1ccc(-n2cnc(-c3c(-c4ccccc4)noc3C)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
GAA P10253 2/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 3/20 0.45
CACNA1F O60840 1/20 0.45
CACNA1D Q01668 1/20 0.45
CACNA1S Q13698 1/20 0.45
CACNA1C Q13936 1/20 0.45
P2RY12 Q9H244 1/20 0.44
GABRA5 P31644 1/20 0.43
RARA P10276 1/20 0.43
RARB P10826 1/20 0.43
RARG P13631 1/20 0.43
POLB P06746 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2470861 0.90 JMJD6 (0.46) L3MBTL1GAALMNASMN1; SMN2MAPT
SCHEMBL2471573 0.88 PTGS2 (0.47) L3MBTL1GAALMNASMN1; SMN2MEN1
SCHEMBL2471395 0.87 MAPK14 (0.48) GAALMNASMN1; SMN2MEN1MAPT
SCHEMBL2473691 0.85 L3MBTL1 (0.48) L3MBTL1LMNASMN1; SMN2MAPTHTT
SCHEMBL2470757 0.83 PTGS2 (0.56) L3MBTL1LMNAMAPTHTTKMT2A
SCHEMBL2477859 0.82 HTT (0.55) L3MBTL1GAALMNAMAPTHTT
SCHEMBL2475025 0.82 MAPK14 (0.50) LMNASMN1; SMN2ALDH1A1TSHRMAPK1
SCHEMBL2524137 0.82 MAPK14 (0.42) L3MBTL1GAALMNASMN1; SMN2MEN1
SCHEMBL2473672 0.81 KDM5B (0.44) GABRA5MAPK14PTGS1PTGS2
SCHEMBL14562176 0.81 GABRA5 (0.53) L3MBTL1LMNASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968973-B1 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-10-05 EP disclosed
US-7414061-B2 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-08-19 US disclosed
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives GABRA5, GABRA4, GABRA1 L3MBTL1 3361/4885GAA 736/4885LMNA 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.